June 5, 2017 / 10:41 AM / 2 months ago

BRIEF-Vical presents phase 1 VL-2397 data at June ASM microbe 2017 meeting supporting advancement to phase 2

1 Min Read

June 5 (Reuters) - Vical Inc

* Vical Inc - presents phase 1 vl-2397 data at June ASM microbe 2017 meeting supporting advancement to phase 2

* Vl-2397 appeared safe and well-tolerated with favorable pharmokinetic profile in healthy subjects

* Vical Inc - phase 2 initiation is planned for Q4 of 2017

* Vical - safety findings revealed neither treatment-related serious adverse events nor grade 4 treatment-emergent adverse events (teaes) at any dose

* Most common treatment-emergent adverse events in study were infusion site reactions Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below